Polyrizon Ltd Stock Price, News & Analysis

Polyrizon (Nasdaq: PLRZ) has announced positive preclinical results for its PL-14 Allergy Blocker, demonstrating successful intranasal delivery in a collaborative study with the University of Parma. The study showed over 60% deposition of the product in the nasal vestibule, the critical first point of contact for airborne allergens.

The research validates the company's proprietary Capture & Contain (C&C) platform, supporting its mechanism of action as a physical barrier against allergens. The global allergen blocker market, valued at $0.14 billion in 2024, is projected to reach $0.21 billion by 2033, growing at a 4.4% CAGR. The company plans to advance toward clinical trials following these encouraging preclinical results.

Polyrizon (Nasdaq: PLRZ) has successfully retained its Nasdaq listing following a hearing with the Nasdaq Hearings Panel. The company faced potential delisting concerns related to a private placement involving 5,962,073 ordinary shares, including 5,829,389 shares issued through warrant exercises. The Panel granted continued listing subject to meeting the Minimum Bid Price Rule by October 17, 2025.

Following the private placement, Polyrizon reports a cash balance of $15.68 million. The company has committed to avoiding complex financing instruments and is implementing enhanced internal controls for securities issuances and Nasdaq compliance.

Polyrizon (NASDAQ: PLRZ) has announced promising preclinical results for its hydrogel-based Trap & Target (T&T) platform for intranasal drug delivery. In collaboration with the University of Parma, the study demonstrated that the company's hydrogel formulation successfully achieved over 60% targeted deposition in the middle and upper turbinates of the nasal cavity, which is crucial for central nervous system (CNS) drug delivery. The technology shows potential for treating CNS conditions like opioid overdose and epileptic seizures where rapid brain access is critical. The study utilized a silicone-based human nasal cast and fluorescein-traced imaging to validate the delivery system's effectiveness. Polyrizon plans to continue validation through animal models and initiate safety studies as part of its development roadmap.

Polyrizon Ltd. (PLRZ) has received a delisting notification from Nasdaq's Listing Qualifications Department due to concerns over a recent securities issuance. The notification stems from the company's March 31, 2025 securities purchase agreement, specifically regarding Series A warrants with alternate cashless exercise provisions that Nasdaq determined could cause substantial shareholder dilution.

While the notice doesn't result in immediate delisting of PLRZ shares from the Nasdaq Capital Market, the company must request a hearing before a Hearings Panel to maintain its listing. Polyrizon has confirmed its intention to request this hearing, which will automatically stay any suspension or delisting actions pending the hearing's outcome and any additional extension period granted by the Panel.

Polyrizon (NASDAQ: PLRZ) has announced positive preclinical results for its intranasal hydrogel platform. The ex vivo studies, conducted in collaboration with Prof. Fabio Sonvico's laboratory using rabbit nasal mucosa, demonstrated two key technological achievements: strong mucoadhesion and extensive nasal surface coverage. Using two-photon fluorescence microscopy, researchers observed that the formulation spreads rapidly and uniformly across nasal tissues, forming a consistent surface layer. The tests also showed that the formulation maintains strong attachment to nasal tissue even under simulated physiological nasal fluid flow conditions. These properties are crucial for providing effective protection against airborne biological threats and enabling efficient intranasal therapeutic delivery.

Polyrizon Ltd. (NASDAQ: PLRZ) has initiated preclinical studies for intranasal Benzodiazepines (BZDs) using its proprietary Trap and Target™ (T&T) platform to treat acute repetitive seizures (ARS) and status epilepticus. The company is targeting the global acute repetitive seizures market, valued at $3.15 billion in 2024 with projected CAGR of 12.7% from 2025-2030.

The studies will be conducted in collaboration with Professor Fabio Sonvico from the University of Parma, focusing on developing a rapid, targeted, and patient-friendly seizure rescue therapy. The intranasal delivery system aims to provide advantages over traditional administration methods, enabling emergency responders, caregivers, and patients to administer treatment quickly in out-of-hospital settings.

Polyrizon (NASDAQ: PLRZ) has announced successful preliminary safety study results for its PL-14 Allergy Blocker formulation, tested on human nasal tissue using the MucilAir™ model. The study evaluated the local tolerability of the mucoadhesive nasal gel spray, designed to create a physical barrier against airborne allergens with a 4-hour effectiveness window.

The safety assessment measured key indicators including tissue integrity, cytotoxicity, cilia beating frequency, mucociliary clearance, and inflammatory response. Results showed tissue viability and function remained consistent with baseline and vehicle controls, with no signs of inflammatory activation or functional impairment.

This milestone supports Polyrizon's regulatory strategy and upcoming FDA pre-submission meeting. The company plans to initiate U.S. and European clinical trials in late 2025 or early 2026.

Polyrizon (Nasdaq: PLRZ) has received a notification from Nasdaq on April 8, 2025, indicating non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive business days. The company has been granted a 180-day compliance period until October 6, 2025 to meet the requirement.

To regain compliance, PLRZ's closing bid price must exceed $1.00 for at least 10 consecutive business days. If unsuccessful, the company may qualify for an additional 180-day period, provided it meets other Nasdaq Capital Market listing criteria. Failure to comply could result in delisting from Nasdaq.

Polyrizon (Nasdaq: PLRZ) has partnered with a leading global branding and trademark consultancy firm to develop strategic branding for its Capture and Contain™ (C&C) hydrogel technology. The collaboration aims to create brand identity for their innovative intranasal spray formulation, which creates a protective biological barrier against allergens and viruses.

The engagement includes comprehensive trademark screening and linguistic evaluations across U.S. and European markets to ensure brand viability and regulatory compliance. The brand development process is scheduled to align with Polyrizon's ongoing clinical and regulatory milestones.